MOTS-c and NAD+ both live in the mitochondria conversation, which makes them look interchangeable from a distance. They are not. NAD+ is infrastructure: the coenzyme mitochondria burn through in every energy-producing reaction. MOTS-c is a signal: a peptide encoded in mitochondrial DNA that tells the rest of the cell to adjust its metabolism. Comparing them is comparing fuel-system maintenance with a regulatory switch: different mechanisms, different evidence stages, different questions.
| Attribute | MOTS-c | NAD+ |
|---|---|---|
| What it is | Peptide encoded in mitochondrial DNA (a "mitokine" signal) | Coenzyme present in every living cell |
| Studied role | Metabolic regulation via AMPK; exercise-mimetic signalling | Energy metabolism, redox reactions, DNA-repair enzyme fuel |
| Age relationship | Levels rise with exercise; decline with age (observational) | Well-documented decline with age across tissues |
| Key evidence | Animal: improved insulin sensitivity, obesity protection (Cell Metabolism 2015) | Deep basic-science literature; precursor trials raise levels in humans |
| Human data | Observational only; no published trial of injected MOTS-c | Thin for injectable NAD+ itself; more for oral precursors |
| Evidence stage | Discovery-stage (identified 2015) | Mature biology, immature supplementation evidence |
| In the Body Pharm catalogue | Yes (MOTS-C 32) | Yes (NAD+ 1000) |
NAD+ participates directly in the chemistry of energy production. It is consumed, recycled and required, which is why its age-related decline draws so much research attention. MOTS-c does no metabolic work itself; it activates AMPK signalling in skeletal muscle, shifting how cells handle glucose and fat. In the 2015 discovery work and follow-ups, giving it to mice improved insulin sensitivity and blunted diet-induced obesity: a regulatory effect, not a fuel effect.
NAD+ biology is textbook science with decades behind it; what is young is the evidence that supplementing it changes outcomes. MOTS-c is the mirror image: the whole field is barely a decade old, the animal data are striking, and the human data are observational, with no published trial of injected MOTS-c. Neither compound has a completed clinical programme or an approved use.
Because one is a signalling peptide and the other a metabolic substrate, the two are not alternatives answering the same question. Energy-metabolism research often treats regulatory signals and coenzyme availability as separate variables, which is the honest way to read a range that lists both. We sell the two together as the Metabolic Reset set; no published study has given them together.
No. NAD+ is a coenzyme consumed in energy production; MOTS-c is a signalling peptide that regulates metabolism via AMPK. They intersect at mitochondria but act at completely different levels.
Both are thin, in different ways: NAD+ has mature basic science but limited trial data for supplementation itself; MOTS-c has striking animal results and only observational human data.
No. Neither MOTS-c nor injectable NAD+ has a regulator-approved indication or validated human dosing schedule anywhere.
MOTS-c levels rise with exercise in humans, and giving it to animals reproduced part of exercise’s metabolic signature, which is the origin of its "exercise-mimetic" label. That label describes animal findings, not a demonstrated human effect.
This page is educational and intended for research and informational use only. It is not medical advice, a treatment recommendation, or dosing guidance, and it makes no promises about outcomes. Where a compound has held a marketing authorisation, approved medicines are supplied only through licensed pharmacies with a prescription. Body Pharm EU supplies research-grade materials for laboratory use, not approved medicines, and nothing here should be read as a substitute for advice from a qualified healthcare professional.
These two share a shelf and almost nothing else. MOTS-c is a peptide encoded in mitochondrial DNA. NAD+ is a coenzyme and not a peptide at all. They are compared because you probably arrived wanting the same outcome, not because the molecules are alike.
Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab 2015;21(3):443–454. PMID 25738459; Mitochondria-derived peptide MOTS-c: effects and mechanisms. PMC9854231; Effects of NMN on glucose and lipid metabolism: meta-analysis of RCTs. PMID 39531138; Safety and metabolism of long-term NIAGEN (nicotinamide riboside chloride). PMC6611812
MOTS-c is a 16-amino-acid peptide encoded by a short open reading frame within the mitochondrial 12S ribosomal RNA: mitochondrial DNA, not nuclear. It acts as a signalling molecule (what MOTS-c is), and we supply it as MOTS-C 32.
NAD+ is a coenzyme participating directly in redox reactions (what NAD+ is); ours is NAD+ 1000. It does not bind a receptor and issue an instruction, so the receptor-selectivity frame that explains most of this catalogue simply does not apply to it.
A comparison table that puts them in adjacent columns implies a like-for-like that does not exist. Whether something is a peptide, protein or coenzyme comes first. We set the category confusion out at mitochondrial peptides.
MOTS-c: every published finding is cell culture or rodent. In mice it prevented age-dependent and high-fat-diet-induced insulin resistance and prevented diet-induced obesity, via inhibition of the folate cycle, a greater-than-twentyfold rise in endogenous AICAR, and AMPK activation. No published human efficacy trial exists: no established human dose, no human safety dataset, no clinical outcome data.
NAD+: a real human trial literature, though mostly concerning the oral precursors rather than NAD+ itself. It shows the biomarker rises reliably while downstream outcomes are inconsistent by endpoint.
So one has a mechanism and no human data; the other has human data whose results are mixed. Neither is the straightforward winner a comparison page usually names.
Nothing has compared them. Given that one has no human efficacy data at all, there is nothing to compare against. The two pens are sold together as the Metabolic Reset set, and no published study has given the two compounds together either.
Queries about MOTS-c surface PubMed Central, anti-doping bodies and reference sources rather than merchants, which reflects a genuine and active research literature. That literature is preclinical. Volume of publication is not the same as clinical evidence.
And in the other direction: raw search interest in “NAD” substantially overstates interest in the compound, because the abbreviation matches unrelated medical usage.
Neither holds a marketing authorisation. The oral NAD+ precursors are generally sold as food supplements, a third framework again.
Related: NAD+ vs NMN, peptides for energy.
We use cookies for analytics and marketing to improve your experience. You can accept or reject non-essential cookies. Privacy Policy